Lanreotide is a Medicine belongs to Endocrine drugs group whose information about Brand can be referenced from   Book : Martindale    Page : 1960   Edition : 37  

  ►   Brandname : Somatuline
  ►  Strength :

A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : SC, IM
Reference :-   Book : Martindale    Page : 1960   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 IM 30 mg Injection Dose: Given every 14 days.
2 Acromegaly SC 60 mg Injection Dose: Given once every 28 days may be used in treatment-naive patients
3 Neuroendocrine tumours SC 60 120 mg Injection Dose: Given once every 28 days and adjusted according to symptomatic relief.

Ref :-  Book : Martindale    Page : 1960   Edition : 37  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :
►  Side Effect : Anorexia, Nausea, Vomiting, Diarrhoea, Steatorrhoea, Abdominal discomfort, Flatulence, Pancreatitis, Hepatic dysfunction, Gall stones formation, Thyroid dysfunction, Hypoglycaemia, Hyperglycaemia, Impaired glucose tolerance
Ref :-   Book : Martindale    Page : 1960-1961   Edition : 37.  

►  Drug Interaction : Drug interaction of Lanreotide is with , Calcium Channel Blockers , Beta Blockers , Oral Hypoglycemic Drugs,  Bromocriptine , Insulin
Ref :-   Book : Martindale    Page : 1961   Edition : 37.  

  ►    Mechanism of Drug Drug Interaction :  Lanreotide has been associated with alterations in nutrient absorption and there is a theoretical possibility that it may affect the oral absorption of other drugs. Patients receiving insulin or oral hypoglycaemics may require dose adjustments of these drugs if lanreotide is also used. The bioavailability of bromocriptine is increased by lanreotide . It has been suggested that dosage of beta blockers, calcium-channel blockers, or drugs to control fluid and electrolyte balance may also need to be adjusted.
Ref :-   Book : Martindale    Page : 1961   Edition : 37.  

►  Contraindication : pancreatitis, Hepatic dysfunction
Ref :-   Book : Martindale    Page : 1960-1961   Edition : 37.  
  ►  Mechanism of Action :   Lanreotide is a somatostatin analogue. Somatostatin is a polypeptide obtained from the hypothalamus or by synthesis. The naturally occurring form has a cyclic structure. Although somatostatin derived from the hypothalamus is a 14-amino-acid peptide, a longer, 28-amino-acid form also exists in some tissues. Somatostatin inhibits the release of growth hormone from the anterior pituitary. It also inhibits the release of thyrotrophin and corticotropin from the pituitary, glucagon and insulin from the pancreas, and appears to have a role in the regulation of duodenal and gastric secretions. In the CNS it appears to play a role in the perception of pain.
Ref :-   Book : Martindale    Page : 1960,1967   Edition : 37.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA

DIETARY Substance Interactions

​   ► This Medicine interact with :- NA

ContraIndication DIETARY Substance

​   ► This Medicine contraindicate with :- NA

►   Route of Elimination :   NA

►    Plasma Half-life :   Min value :-   2.5 hours,    Max value :-   NA
Ref :-   Book : Martindale    Page : 1960   Edition : 37.  

►    Peak Plasma Concentration :   Min value :-   nf,    Max value :-   NA
Ref :-   Book :    Page :    Edition : .